KM
KMDA.US Kamada
- Market cap
- USD 467M
- P/E
- 21.3x
- P/B
- 1.74x
- ROE
- 10.6%
- Dividend yield
- 2.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KMDA.US undervalued?
Graham numberKMDA.US trades 28.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kamada fundamental analysis
No fundamental analysis for Kamada yet.
Kamada stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and p…
Full company profileKamada financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kamada annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 77.5M | 103M | 114M | 127M | 133M | 104M | 129M | 143M | 161M | 180M | 202M |
| Gross Profit | 21.7M | 32.1M | 41.5M | 49.7M | 47.6M | 30.3M | 46.7M | 55.5M | 70.0M | 76.4M | 86.0M |
| Operating Income | -5.84M | 7.44M | 19.3M | 22.8M | 19.2M | -696K | 4.53M | 10.1M | 20.1M | 26.2M | 35.5M |
| EBITDA | -1.38M | 11.1M | 23.6M | 27.8M | 25.1M | 4.01M | 10.8M | 22.4M | 27.8M | 39.2M | 49.2M |
| Net Income | -6.73M | 6.90M | 22.3M | 22.3M | 17.1M | -2.23M | -2.32M | 8.28M | 14.5M | 20.2M | 28.3M |
| EPS | -0.18 | 0.18 | 0.55 | 0.55 | 0.38 | -0.05 | -0.05 | 0.15 | 0.25 | 0.35 | 0.49 |
| Balance Sheet | |||||||||||
| Total Assets | 99.7M | 122M | 138M | 174M | 211M | 319M | 322M | 355M | 372M | 379M | 382M |
| Total Liabilities | 33.0M | 32.6M | 25.7M | 38.5M | 32.0M | 142M | 146M | 111M | 113M | 110M | 114M |
| Shareholders' Equity | 66.7M | 89.5M | 112M | 135M | 179M | 177M | 176M | 244M | 259M | 269M | 268M |
| Cash & Short-term Investments | 28.6M | 43.0M | 50.6M | 73.9M | 109M | 18.6M | 34.3M | 55.6M | 78.4M | 75.5M | 75.3M |
| Total Debt | 1.78M | 1.98M | 1.28M | 5.75M | 4.94M | 24.4M | 20.6M | 8.82M | 11.1M | 11.6M | 11.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.90M | 3.89M | 10.5M | 28.4M | 19.1M | -9.17M | 28.6M | 4.32M | 47.6M | 27.6M | 49.7M |
| Capital Expenditure | 2.64M | 4.45M | 2.88M | 2.37M | 5.49M | 3.88M | 3.78M | 5.85M | 10.7M | 10.7M | 8.77M |
| Free Cash Flow | -744K | -559K | 7.66M | 26.1M | 13.6M | -13.0M | 24.8M | -1.54M | 36.9M | 16.9M | 41.0M |
| Ratios | |||||||||||
| ROE | -10.1% | 7.7% | 19.8% | 16.4% | 9.6% | -1.3% | -1.3% | 3.4% | 5.6% | 7.5% | 10.6% |
| ROA | -6.8% | 5.7% | 16.1% | 12.8% | 8.1% | -0.7% | -0.7% | 2.3% | 3.9% | 5.3% | 7.4% |
| Net Profit Margin | -8.7% | 6.7% | 19.5% | 17.5% | 12.9% | -2.2% | -1.8% | 5.8% | 9.0% | 11.2% | 14.0% |
| Debt to Equity | 0.03x | 0.02x | 0.01x | 0.04x | 0.03x | 0.14x | 0.12x | 0.04x | 0.04x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kamada dividends
- Dividend yield
- 2.67%
- Forward dividend
- 0.17 USD
- Payout ratio
- 61.8%
- Ex-dividend date
- Nov 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 12.5M | 0.21 | 61.8% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1019:1000 on Aug 25, 2010.
Who owns Kamada
- Insiders 7.11%
- Institutions 49.35%
- Public & others 43.53%
- Shares outstanding 57.7M
- Free float 32.7M
Top funds holding KMDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| DFA International Small Company I | 199K | 0.34% | -0.01% | Sep 2026 |
| DFA International Core Equity 2 I | 98.5K | 0.17% | 0.00% | Sep 2026 |
| Dimensional International Sm Cp Val ETF | 70.7K | 0.12% | +0.76% | Oct 2026 |
| DFA International Small Cap Value I | 56.7K | 0.10% | +23.53% | Sep 2026 |
| Dimensional International Small Cap ETF | 53.7K | 0.09% | 0.00% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 51.2K | 0.09% | +0.20% | Oct 2026 |
| WisdomTree International SmallCp Div ETF | 42.8K | 0.07% | 0.00% | Oct 2026 |
| Dimensional International Core Eq 2 ETF | 35.8K | 0.06% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 33.1K | 0.06% | -11.71% | Aug 2026 |
| Dimensional Global Trgtd Value USD Acc | 25.8K | 0.04% | -0.41% | Sep 2026 |
| Mandarine Global Microcap G EUR | 25.0K | 0.04% | 0.00% | Jul 2026 |
| Acuitas Small Cap Active ETF | 24.0K | 0.04% | 0.00% | Oct 2026 |
| Dimensional World ex US Core Eq 2 ETF | 20.2K | 0.03% | 0.00% | Oct 2026 |
| WisdomTree Dynamic Intl SmCap Eq ETF | 17.5K | 0.03% | 0.00% | Oct 2026 |
| RAM (Lux) Sys Emg Mkts Equities B USD | 16.4K | 0.03% | 0.00% | Sep 2026 |
| Dimensional International Cr Eq Mkt ETF | 11.3K | 0.02% | 0.00% | Oct 2026 |
| Marsot Inversions SICAV SA | 10.3K | 0.02% | 0.00% | Oct 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 9.18K | 0.02% | -2.32% | Jun 2026 |
| DFA World ex US Core Equity Instl | 8.92K | 0.02% | 0.00% | Sep 2026 |
| iShares International Sm-Cp Eq Fac ETF | 8.85K | 0.02% | 0.00% | Oct 2026 |
Top institutions holding KMDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Phoenix Financial Ltd | 1.65M | 2.87% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 820K | 1.42% | +10.40% | Sep 2026 |
| Wells Fargo & Co | 592K | 1.03% | -0.87% | Jun 2026 |
| Acadian Asset Management LLC | 451K | 0.78% | +191.88% | Sep 2026 |
| Dimensional Fund Advisors, Inc. | 330K | 0.57% | +9.52% | Sep 2026 |
| ARK Investment Management LLC | 263K | 0.46% | -2.32% | Jun 2026 |
| Two Sigma Investments LLC | 151K | 0.26% | -22.21% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 75.2K | 0.13% | -49.88% | Jun 2026 |
| Man Group PLC | 61.9K | 0.11% | +13.02% | Jun 2026 |
| The Goldman Sachs Group Inc | 59.0K | 0.10% | -19.07% | Jun 2026 |
| LSV Asset Management | 47.8K | 0.08% | 0.00% | Sep 2026 |
| BlackRock Inc | 45.4K | 0.08% | +1.90% | Jun 2026 |
| Stifel Financial Corp | 38.4K | 0.07% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 37.5K | 0.07% | 0.00% | Jun 2026 |
| Aristides Capital LLC | 36.0K | 0.06% | +4.46% | Jun 2026 |
| XTX Topco Ltd | 31.4K | 0.05% | 0.00% | Jun 2026 |
| Trexquant Investment LP | 27.7K | 0.05% | +156.73% | Jun 2026 |
| Vident Advisory, LLC | 24.0K | 0.04% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 21.3K | 0.04% | -27.47% | Jun 2026 |
| Altshuler Shaham Ltd | 20.6K | 0.04% | +5,758.69% | Jun 2026 |
Kamada company profile
- Company name
- Kamada
- Ticker
- KMDA.US
- ISIN
- IL0010941198
- Exchange
- USA Stocks
- Listed since
- May 31, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 462
- Fiscal year end
- December
- Address
- 2 Holzman Street, Rehovot, Israel, 7670402
- Phone
- 972 8 940 6472
- Website
- kamada.com
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Kamada management
10- Mr. Amir LondonChief Executive Officer · born 1969
- Mr. Chaime OrlevChief Financial Officer · born 1970
- Mr. Eran NirChief Operating Officer · born 1973
- Mr. Jon R. KnightVice President of US Commercial Operations · born 1966
- Mr. Boris GorelikVice President of Business Development & Strategic Programs · born 1982
- Mr. David TsurCo-Founder & Independent Deputy Chairman of the Board · born 1950
- Mr. Nir Livneh B.A., L.L.B.VP, General Counsel & Corporate Secretary · born 1979
- Ms. Hanni NehemanVice President of Marketing & Sales · born 1970
- Ms. Liron ReshefVice President of Human Resources · born 1972
- Ms. Shavit BeladevVice President of Kamada Plasma · born 1971